Binimetinib for relapsed or refractory hairy cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called binimetinib in people with a type of leukemia that has come back or not responded to treatment. It is for those whose cancer cells do not have a BRAF mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hairy cell leukemia (HCL) or a variant that has come back or not responded to at least one prior treatment.
- Your cancer cells must not have a BRAF mutation (BRAF wild type).
- You need to have a low blood count, an enlarged spleen, or other signs that you need treatment.
- You must be 18 years or older.
- Your liver, kidney, and blood clotting function must meet certain levels.
- You cannot have had chemotherapy, immunotherapy, or radiation in the last 2 weeks.
- You must be willing to use effective birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
This trial studies the best way to treat hairy cell leukemia and checks how well the approach works in people who need treatment for their disease. It may help if you have classic hairy cell leukemia and have not had certain prior chemotherapy.
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
Hear when a new Hairy Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.